Ablation for lung spots in advanced liver cancer patients
Looks at lung spot ablation with drug therapy in advanced liver cancer.
Plain-language title generated from the registry record
Registry title: Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06644430, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT06644430
- Record updated
- 23 October 2026
- Original description
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.Read full original descriptionShow less
Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.
Inclusion: diagnosis of primary or recurrent HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases; presence of pulmonary oligometastasis; metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm; receipt of first-line systemic therapy for minimum of 3 months before ablation; undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included; classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; no history of other malignancies; life expectancy more than 3 months; agreed to participated in this clinical trial; Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.
Exclusion: no response to systemic therapy; age < 18 years or > 75 years; intermediate HCC; advanced HCC with more than five metastases; metastases size > 5 cm; life expectancy less than 3 months.